Holen Sie sich die Stockscreener-App
13.05
1.58%
-0.21
Handel nachbörslich:
13.01
-0.04
-0.31%
Schlusskurs vom Vortag:
$13.26
Offen:
$13.12
24-Stunden-Volumen:
975.90K
Relative Volume:
0.69
Marktkapitalisierung:
$1.46B
Einnahmen:
$577.74M
Nettoeinkommen (Verlust:
$-149.78M
KGV:
-9.3214
EPS:
-1.4
Netto-Cashflow:
$-78.21M
1W Leistung:
+0.27%
1M Leistung:
-3.19%
6M Leistung:
+8.39%
1J Leistung:
-48.58%
1-Tages-Spanne:
$12.91
$13.24
1-Wochen-Bereich:
$12.91
$14.29
52-Wochen-Spanne:
$10.70
$26.46
Novocure Ltd Stock (NVCR) Company Profile
Firmenname
Novocure Ltd
Sektor
Branche
Telefon
44 (0)15 3475 6700
Adresse
NO. 4 THE FORUM, ST. HELIER
Vergleichen Sie NVCR mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NVCR
Novocure Ltd
|
13.05 | 1.48B | 577.74M | -149.78M | -78.21M | -1.40 |
|
ABT
Abbott Laboratories
|
108.27 | 189.14B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
BSX
Boston Scientific Corp
|
93.61 | 138.74B | 19.35B | 2.78B | 3.82B | 1.8696 |
|
SYK
Stryker Corp
|
354.57 | 136.52B | 24.38B | 2.94B | 4.07B | 7.6159 |
|
MDT
Medtronic Plc
|
100.69 | 129.06B | 34.76B | 4.79B | 5.21B | 3.7017 |
|
EW
Edwards Lifesciences Corp
|
83.60 | 48.90B | 5.88B | 1.34B | 799.60M | 2.3489 |
Novocure Ltd Stock (NVCR) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-07-25 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2025-07-08 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2024-12-02 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2024-10-16 | Hochstufung | H.C. Wainwright | Neutral → Buy |
| 2023-11-20 | Fortgesetzt | JP Morgan | Neutral |
| 2023-08-28 | Herabstufung | H.C. Wainwright | Buy → Neutral |
| 2023-08-08 | Hochstufung | Piper Sandler | Neutral → Overweight |
| 2023-08-04 | Eingeleitet | SVB Securities | Outperform |
| 2023-07-31 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2023-06-07 | Hochstufung | Wedbush | Underperform → Neutral |
| 2023-05-16 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2023-03-17 | Herabstufung | JP Morgan | Neutral → Underweight |
| 2023-01-06 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2023-01-05 | Bestätigt | H.C. Wainwright | Buy |
| 2022-11-29 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2022-10-24 | Herabstufung | Piper Sandler | Overweight → Neutral |
| 2022-07-05 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2022-05-16 | Eingeleitet | H.C. Wainwright | Buy |
| 2022-02-08 | Eingeleitet | Loop Capital | Buy |
| 2022-02-02 | Hochstufung | Oppenheimer | Perform → Outperform |
| 2022-01-20 | Hochstufung | Truist | Hold → Buy |
| 2022-01-03 | Hochstufung | Evercore ISI | Underperform → In-line |
| 2021-07-01 | Herabstufung | Mizuho | Buy → Neutral |
| 2021-04-14 | Herabstufung | Wedbush | Neutral → Underperform |
| 2021-01-25 | Bestätigt | Piper Sandler | Overweight |
| 2020-09-23 | Eingeleitet | Northland Capital | Outperform |
| 2020-09-18 | Herabstufung | Wells Fargo | Overweight → Equal Weight |
| 2020-09-17 | Herabstufung | Truist | Buy → Hold |
| 2020-06-01 | Fortgesetzt | Oppenheimer | Perform |
| 2020-05-01 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2020-04-09 | Herabstufung | Evercore ISI | In-line → Underperform |
| 2020-03-05 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2020-01-02 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2019-07-29 | Hochstufung | SunTrust | Hold → Buy |
| 2019-07-26 | Herabstufung | JP Morgan | Overweight → Neutral |
| 2019-07-26 | Herabstufung | Wedbush | Outperform → Neutral |
| 2019-03-20 | Eingeleitet | SunTrust | Hold |
| 2018-11-02 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2018-07-16 | Eingeleitet | Evercore ISI | Outperform |
| 2018-04-18 | Bestätigt | Mizuho | Buy |
| 2018-02-23 | Bestätigt | Mizuho | Buy |
| 2017-05-24 | Hochstufung | Wells Fargo | Market Perform → Outperform |
| 2016-07-29 | Bestätigt | Wedbush | Outperform |
| 2016-01-19 | Eingeleitet | Barclays | Underweight |
| 2015-12-02 | Eingeleitet | Deutsche Bank | Hold |
Alle ansehen
Novocure Ltd Aktie (NVCR) Neueste Nachrichten
Emerald Mutual Fund Advisers Trust Has $248,000 Stock Position in NovoCure Limited $NVCR - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Short Interest Update - MarketBeat
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of “Hold” from Analysts - Defense World
NovoCure’s (NVCR) “Neutral” Rating Reaffirmed at Wedbush - Defense World
Assessing NovoCure: Insights From 4 Financial Analysts - Benzinga
NovoCure (NVCR) Rating Reiterated as Neutral by Wedbush | NVCR S - GuruFocus
A Look At NovoCure (NVCR) Valuation After Record 2025 Revenue And CEO Transition - simplywall.st
NovoCure (NASDAQ:NVCR) Receives Neutral Rating from Wedbush - MarketBeat
HC Wainwright Has Bullish Estimate for NovoCure Q4 Earnings - MarketBeat
Leerink Partners Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $24 - Futubull
NovoCure Limited (NASDAQ:NVCR) Receives Average Rating of "Hold" from Analysts - MarketBeat
Brokers Set Expectations for NovoCure FY2030 Earnings - Defense World
HC Wainwright Comments on NovoCure FY2030 Earnings - MarketBeat
NovoCure (NASDAQ:NVCR) Given New $39.00 Price Target at HC Wainwright - Defense World
Is NovoCure (NVCR) A Rare Opportunity After A 45.9% One Year Share Price Fall - simplywall.st
Why NovoCure Is Failing To Disrupt NSCLC (NASDAQ:NVCR) - Seeking Alpha
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating By Investing.com - Investing.com Nigeria
HC Wainwright & Co. Maintains Buy Rating on NVCR, Lowers Price T - GuruFocus
HC Wainwright Has Lowered Expectations for NovoCure (NASDAQ:NVCR) Stock Price - MarketBeat
NovoCure stock holds steady as H.C. Wainwright reiterates Buy rating - Investing.com
H.C. Wainwright Maintains Novocure(NVCR.US) With Buy Rating, Cuts Target Price to $39 - 富途牛牛
Novocure reports $655 million in preliminary 2025 revenue By Investing.com - Investing.com South Africa
Novocure (NVCR) Surpasses Revenue Expectations with Strong FY25 Performance - GuruFocus
Cancer therapy Novocure hits record sales, awaits 2026 trial results - Stock Titan
Can NovoCure Limited stock double in next 5 years2025 Bull vs Bear & Low Risk High Reward Trade Ideas - Улправда
Will NovoCure Limited stock split attract more investorsProfit Target & Safe Capital Allocation Plans - ulpravda.ru
Can NovoCure Limited stock surprise with earnings upsideEarnings Performance Report & Scalable Portfolio Growth Methods - Улправда
How NovoCure Limited stock reacts to global recession fears2025 Geopolitical Influence & Entry and Exit Point Strategies - ulpravda.ru
How analysts rate NovoCure Limited stock todayMarket Growth Report & Safe Investment Capital Preservation Plans - Улправда
Will NovoCure Limited stock outperform tech sector in 2025Portfolio Growth Summary & Community Verified Watchlist Alerts - Улправда
Total debt per share of NovoCure Ltd. – GETTEX:038 - TradingView — Track All Markets
Voya Investment Management LLC Sells 64,539,786 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure Ltd (NVCR) Product Pipeline Analysis Report 2025ResearchAndMarkets.com - Bluefield Daily Telegraph
Why NovoCure Limited stock could be next big winnerChart Pattern Recognition & View Live Stock Forecasts Instantly - bollywoodhelpline.com
NovoCure (NVCR): Assessing Valuation After a Recent Rebound From Multi‑Month Lows - Yahoo Finance UK
Has NovoCure’s Tumor Treating Fields Progress Created a Value Opportunity After the 2025 Share Slump? - Yahoo Finance
NovoCure (NVCR): Exploring Valuation After a Recent Share Price Rebound - simplywall.st
Novocure (NVCR) Q2 2025 Earnings Call Transcript - AOL.com
NovoCure (NVCR) Q3 2024 Earnings Call Transcript - The Globe and Mail
First Week of February 2026 Options Trading For NovoCure (NVCR) - Nasdaq
How to hear Novocure’s CEO speak at the J.P. Morgan healthcare event - Stock Titan
NovoCure Limited (NASDAQ:NVCR) Receives Consensus Recommendation of "Hold" from Brokerages - MarketBeat
CapEx per share of NovoCure Ltd. – MUN:038 - TradingView — Track All Markets
Wells Fargo Keeps Their Hold Rating on NovoCure (NVCR) - The Globe and Mail
NovoCure (NVCR): Assessing Valuation After the CEO Transition From Ashley Cordova to Frank Leonard - simplywall.st
NovoCure’s LUNAR-2 Study: A New Horizon in Lung Cancer Treatment - MSN
Does NovoCure’s (NVCR) Internal CEO Transition Reinforce or Recast Its Tumor Treating Fields Strategy? - simplywall.st
Marshall Wace LLP Sells 392,992 Shares of NovoCure Limited $NVCR - MarketBeat
NovoCure (NVCR): Assessing Valuation After a Steep Drawdown and Recent Share Price Uptick - simplywall.st
Does NovoCure's (NVCR) Insider CEO Transition Strengthen Its Long-Term Oncology Strategy Or Limit Change? - Yahoo Finance
Finanzdaten der Novocure Ltd-Aktie (NVCR)
Umsatz
Nettogewinn
Free Cashflow
ENV
2.36%
0.96%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):